Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?

Kenneth Blum^{1,2,3,4,5,6,8*}, Marlene Oscar-Berman⁷, Seth H Blum⁸, Margaret A Madigan⁶, Roger L Waite⁶, Thomas McLaughlin⁸ and Debmalya Barh⁵

¹Department of Psychiatry, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Fl., USA

²Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT, USA

³Department of Addiction Research and Therapy, Malibu Beach Recovery Center, Malibu Beach, CA, USA

⁴Dominion Diagnostics, LLC, North Kingstown, RI, USA

⁵Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India

⁶IGENE, LLC, Austin, Texas, USA

⁷omi_departments of Psychiatry, Neurology, Anatomy and Neurobiology, Boston University of School of Medicine, Boston VA Healthcare System, Boston, MA, 02118, USA

⁸Department of Nutrigenomics, RDSolutions, LLC, La Jolla, CA, USA

^*Corresponding Author: Kenneth Blum, Department of Psychiatry, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA, Tel: 619-890-2167 Email: